Literature DB >> 22430966

Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions.

Rebecca A Keel1, Jared L Crandon, David P Nicolau.   

Abstract

In vivo pharmacokinetics are often evaluated in only one variation of an infection model, and the resulting exposures are assumed to be similar in each model. We evaluated and compared the effect of lung infection and immune status on the murine pharmacokinetics and pulmonary disposition of tedizolid and linezolid. Both factors resulted in differing blood and pulmonary exposure profiles, with similar trends for tedizolid and linezolid. These data highlight the importance of pharmacokinetic confirmation in each model.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22430966      PMCID： PMC3370766          DOI： 10.1128/AAC.06121-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy.

Authors:  Hisham M Ziglam; David R Baldwin; Ian Daniels; Jenny M Andrew; Roger G Finch
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

2.  In vivo pharmacodynamics of a new oxazolidinone (linezolid).

Authors:  D Andes; M L van Ogtrop; J Peng; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.

Authors:  Jared L Crandon; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

4.  Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.

Authors:  P Prokocimer; P Bien; J Surber; P Mehra; C DeAnda; J B Bulitta; G R Corey
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

5.  In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.

Authors:  Arnold Louie; Weiguo Liu; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

6.  Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).

Authors:  Jeffrey B Locke; Mark Hilgers; Karen Joy Shaw
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

7.  Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models.

Authors:  Kerry L LaPlante; Steven N Leonard; David R Andes; William A Craig; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

8.  Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.

Authors:  Somvadee Laohavaleeson; Pamela R Tessier; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

9.  Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.

Authors:  Pornpan Koomanachai; Jared L Crandon; Mary Anne Banevicius; Li Peng; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191
  9 in total
  12 in total

1.  Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections.

Authors:  Shalini Yapa; Jian Li; Christopher J H Porter; Roger L Nation; Kashyap Patel; Michelle P McIntosh
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

2.  Human-Simulated Antimicrobial Regimens in Animal Models: Transparency and Validation Are Imperative.

Authors:  Christian M Gill; Tomefa E Asempa; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

3.  Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.

Authors:  Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

4.  Linezolid decreases susceptibility to secondary bacterial pneumonia postinfluenza infection in mice through its effects on IFN-γ.

Authors:  Jessica M Breslow-Deckman; Cynthia M Mattingly; Susan E Birket; Samantha N Hoskins; Tam N Ho; Beth A Garvy; David J Feola
Journal:  J Immunol       Date:  2013-07-05       Impact factor: 5.422

5.  Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model.

Authors:  Wonhee So; Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

6.  Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis.

Authors:  Mahmoud Tareq Abdelwahab; Sean Wasserman; James C M Brust; Keertan Dheda; Lubbe Wiesner; Neel R Gandhi; Robin M Warren; Frederick A Sirgel; Graeme Meintjes; Gary Maartens; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2021-09-20       Impact factor: 5.191

7.  Tissue pharmacokinetics of cefazolin in patients with lower limb infections.

Authors:  Amira A Bhalodi; Seth T Housman; Ashley Shepard; James Nugent; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

8.  Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.

Authors:  Amira A Bhalodi; Jared L Crandon; Donald Biek; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

9.  Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.

Authors:  Rokeya Tasneen; Fabrice Betoudji; Sandeep Tyagi; Si-Yang Li; Kathy Williams; Paul J Converse; Véronique Dartois; Tian Yang; Carl M Mendel; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

10.  Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model.

Authors:  Lindsay M Avery; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.